Monopar Therapeutics (MNPR) EBIT (2017 - 2026)

Monopar Therapeutics has reported EBIT for 9 years, with the latest figure at -$4.1 million in Q3 2025.

• Quarterly EBIT fell 159.89% year-over-year to -$4.1 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$12.1 million (down 69.49% YoY) and the FY2025 annual result came in at $8.5 million, up 258.12% from the prior year.
• EBIT retreated to -$4.1 million in Q3 2025 per MNPR's latest filing, from -$3.2 million in the prior quarter.
• Over five years, EBIT peaked at -$1.6 million in Q3 2024 and troughed at -$4.1 million in Q3 2025.
• A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for EBIT.
• The sharpest annual moves came in 2024 and 2025: EBIT jumped 31.75% in 2024, then plunged 159.89% in 2025.
• Over 5 years, EBIT stood at -$2.7 million in 2021, then fell by 8.5% to -$2.9 million in 2022, then grew by 28.98% to -$2.1 million in 2023, then grew by 23.77% to -$1.6 million in 2024, then slumped by 159.89% to -$4.1 million in 2025.
• According to Business Quant data, EBIT over the past three periods registered -$4.1 million, -$3.2 million, and -$3.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.